Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer
- 1 September 1990
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 16 (2) , 111-117
- https://doi.org/10.1007/bf01809295
Abstract
Ten year disease-free survival (DFS) results of the Naples randomized trial of adjuvant tamoxifen (TM), 30 mg per day for 2 years versus no therapy according to receptor levels, are reported. From Feb. 1, 1978, through Dec. 31, 1983, 308 pre- and postmenopausal patients with early breast cancer entered the trial. Estrogen receptor (ER) data were available on 239 (77.6%) patients, progesterone receptor (PgR) data on 194 (63.0%), and both receptor data on 181 (58.8%). ER and PgR were assayed by dextran-coated charcoal technique in a single laboratory. The effect of adjuvant TM was significantly related to ER and PgR concentration of the primary tumor. The greatest TM benefit on DFS was evident in patients with the highest levels of receptors. The interaction between the treatment effect and receptor concentration was found whether ER and PgR were considered separately or together.Keywords
This publication has 25 references indexed in Scilit:
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.1988
- ADJUVANT THERAPY WITH TAMOXIFEN IN OPERABLE BREAST CANCER: 10 year results of the Naples (GUN) studyThe Lancet, 1988
- The control of hormone-dependent breast cancer growth—Are we talking about estrogen alone?European Journal of Cancer and Clinical Oncology, 1988
- DEMONSTRATION OF ESTROGEN-RECEPTORS BY MONOCLONAL-ANTIBODY IN FORMALIN-FIXED BREAST-TUMORS1988
- The Stockholm trial on adjuvant tamoxifen in early breast cancerBreast Cancer Research and Treatment, 1987
- Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cellsCell, 1987
- BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUESThe Lancet, 1985
- Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancerPublished by Elsevier ,1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958